Patent SG-11201809688R-A (SG)
Title: Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
Inventor: HOSSAIN SAZZAD
IPC: A61P17/00
Filed: 2017-05-04
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 11 11111111111111 01011101110111110111111111011111110111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/190249 Al 09 November 2017 (09.11.2017) W I P0 I P C T (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/352 (2006.01) A61K 31/415 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/05 (2006.01) A61K 31/4162 (2006.01) A61K 31/122 (2006.01) A61K 31/4172 (2006.01) Published: A61K 31/343 (2006.01) A61K 31/473 (2006.01) — with international search report (Art. 21(3)) A61K 31/397 (2006.01) A61K 31/5383 (2006.01) A61K 31/404 (2006.01) A61P 17/00 (2006.01) (21) International Application Number: PCT/CA2017/050546 (22) International Filing Date: 04 May 2017 (04.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/331,633 04 May 2016 (04.05.2016) US (71) Applicant: INMED PHARMACEUTICALS INC. [CA/CA]; Suite 350-409 Granville Street, Vancouver, British Columbia V6C 1T2 (CA). Inventor: HOSSAIN, Sazzad; 108-8611 Ackroyd Road, Richmond, British Columbia V6X 3P4 (CA). = (72) = Agent: MEE, Trevor R. et al.; Kirby Eades Gale Baker, 100 Murray Street, Suite 500, Ottawa, Ontario K1N OA1 (74) = (CA). Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, — = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every = (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = — 1-1 C:r 71- (54) Title: USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA e•1 AND RELATED CONNECTIVE TISSUE DISORDERS 0 C'N (57) : Mutations in keratin genes or the genes that regulate keratin expression can result in epithelial cells lacking sufficient 1-1 ---- structural integrity. The resulting disruption of connective tissue gives rise to inherited disorders such epidermolysis bullosa. It has been ir----- found that various cannabinoids (including mixtures of cannabidiols and cannabinol) upregulate expression of various keratins such 1-1 © that loss of function in other keratin genes may be compensated for. By way of this upregulation, these cannabinoids can be used to f'1 treat epidermolysis bullosa and other connective tissue disorders arising from intermediate filament dysfunction. C